February 23, 2017 06:26 AM EST
Pharma

The FDA opens an in­side track to let No­var­tis race ahead on Zyka­dia as Roche ri­val­ry heats up

John Carroll

Editor & Founder

No­var­tis just leaped for­ward with its can­cer drug Zyka­dia (cer­i­tinib), gain­ing a pri­or­i­ty re­view from the FDA as a front­line treat­ment for ALK-pos­i­tive non …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times